Soluble inhibitors, such as B-cell maturation antigen (BCMA) and vascular endothelial growth factor A (VEGF-A), can impair the functionality of CAR-T cells, which are designed to target and eliminate cancer cells [43,44]. This evidence concerns the gene TNFRSF17 and cancer.